Last updated: February 20, 2026
What is NDC 00832-6048?
NDC 00832-6048 corresponds to Rifampin capsules. Rifampin is an antibiotic used primarily to treat tuberculosis (TB) and other bacterial infections. It is prescribed as part of combination therapy and in some cases for prophylaxis.
Market Overview
Size and Demand
Estimated global rifampin market size was valued at approximately USD 500 million in 2022. The North American market accounts for around 40%, with rapid growth expected in emerging markets due to rising TB incidence.
Key Drivers
- Growing TB prevalence globally, particularly in India, China, and Southeast Asia
- Increased focus on antimicrobial resistance (AMR) management
- Expanded use in latent TB infection (LTBI) treatment
- Governments investing in TB elimination programs
Competitive Landscape
Major manufacturers include:
| Manufacturer |
Market Share |
Notable Products |
| Sanofi (Rifadin) |
45% |
Rifampin, Rifadin |
| Lupin Pharmaceuticals |
15% |
Generic rifampin |
| Sun Pharmaceutical |
10% |
Generic rifampin |
| Others |
30% |
Various generics and formulations |
The market is highly fragmented, with about 20-25 players globally. Patent protections mainly relate to formulation innovations; the active ingredient patent has expired, boosting generic entry.
Regulatory Environment
- US FDA approval process for rifampin capsules
- WHO prequalification program supporting supply in low-income countries
- Patent expiration occurred in the early 2000s, leading to wide generic adoption
Price Projections
Current Pricing
| Region |
Price per capsule (USD) |
Market Context |
| United States |
$0.50–$1.00 |
Generic competition reduces prices |
| India |
$0.05–$0.15 |
Highly price-sensitive, large volume market |
| Europe |
$0.70–$1.20 |
Established generic availability |
| Africa |
$0.10–$0.30 |
Procurement through WHO prequalified suppliers |
Future Price Trends
Expect prices to stabilize or decline slightly over the next 5 years due to increased generic competition, especially in high-volume markets. Prices in the US and Europe will likely remain stable, with modest decreases driven by patent expirations and manufacturing efficiencies.
Projection Assumptions
- Generic market penetration reaches 90% in emerging markets by 2025
- Volume growth of 8-10% annually in TB-endemic regions
- Manufacturing costs decline through scale, expected 2-3% annually
| Year |
Price Range (USD per capsule) |
Comments |
| 2023 |
$0.45–$1.00 |
Current market prices |
| 2025 |
$0.40–$0.85 |
Slight decline due to increased competition |
| 2030 |
$0.35–$0.80 |
Continued price stabilization with effective generics |
Investment and R&D Outlook
- No new patent-protected rifampin formulations are anticipated within the next five years.
- Focus on combination therapies and formulations with improved bioavailability.
- Opportunities exist for biosimilar development to reduce costs further.
Key Challenges
- Pricing pressure from global generic manufacturers
- Regulatory hurdles in certain jurisdictions
- Supply chain disruptions affecting availability
Conclusion
The rifampin capsule market remains robust, driven by global TB control efforts. Prices are likely to decline modestly with the expansion of generics. Companies should focus on operational efficiencies, formulations, and market access strategies to remain competitive.
Key Takeaways
- The global rifampin capsule market was valued at USD 500 million in 2022.
- North America and Europe account for significant market shares, but emerging markets dominate volume.
- Prices range from USD 0.05–$1.20 per capsule, with downward pressure expected.
- Patent expirations have facilitated attribute-driven generic competition.
- Future growth hinges on TB control policies and formulation innovations.
FAQs
Q1: What factors influence rifampin pricing globally?
A1: Market competition, patent status, procurement policies, manufacturing costs, and regional demand.
Q2: How is the market size expected to change over the next five years?
A2: Growth estimated at 8-10% annually in TB-prevalent regions, with prices declining slightly.
Q3: Are there new formulations or patents anticipated for rifampin?
A3: No significant patent filings or new formulations expected within the next five years.
Q4: Which regions are primary drivers of rifampin demand?
A4: India, China, Southeast Asia, and Africa due to high TB prevalence.
Q5: What are the main competitive threats in this market?
A5: Price erosion from generics, supply chain disruptions, and regulatory barriers.
References
-
MarketsandMarkets. (2022). Antitubercular drugs Market. [online] Available at: https://www.marketsandmarkets.com/ [Accessed 23 Jan 2023].
-
World Health Organization. (2021). Global tuberculosis report 2021. Geneva: WHO.
-
Food and Drug Administration. (2022). Rifampin: Drug Approval Information. [online] Available at: https://www.fda.gov/ [Accessed 23 Jan 2023].
-
IQVIA. (2022). Global Markets for Antibiotics. IQVIA Reports.
-
Deloitte. (2022). Global Generic Pharmaceuticals Market. Deloitte Insights.
